Biote (BTMD) Other Current Payables: $-0.0 Mil (As of Mar. 2026)


BTMD Biote Corp BTMD
70 GF Score
Price $2.28
GF Value $3.07
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Biote Other Current Payables?

Biote BTMD +5.07% 70 Other Current Payables is $-0.0 Mil as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 70/100 and a GF Value™ of $3.07 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Biote's Other Current Payables for the quarter that ended in Mar. 2026 was $-0.0 Mil.

Biote's quarterly Other Current Payables stayed the same from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($0.0 Mil) but then declined from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($-0.0 Mil).

Biote's annual Other Current Payables increased from Dec. 2023 ($-0.0 Mil) to Dec. 2024 ($0.0 Mil) but then stayed the same from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($0.0 Mil).

Biote Other Current Payables Related Terms

Biote Other Current Payables Historical Data

* Premium members only.

The historical data trend for Biote's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biote Other Current Payables Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 0.00

Biote Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
BTMD
70GF Score
Biote Corp BTMD
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biote Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $-0.0 Mil mean?
Biote (BTMD) has a Other Current Payables of $-0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biote and its competitors.
Is Biote's Other Current Payables too high?
Biote's current Other Current Payables is $-0.0 Mil. Overall, Biote has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Other Current Payables compare to DCGO and PIII?
Biote's Other Current Payables of $-0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Healthcare Providers & Services company?
A good Other Current Payables depends on the Healthcare Providers & Services industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Biote and its competitors. Biote's current Other Current Payables is $-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $2.28 — trading 25.7% below its estimated fair value. The current Other Current Payables is $-0.0 Mil. Biote's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Biote (BTMD), the current Other Current Payables is $-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $2.28 is trading 25.7% below its estimated GF Value™ of $3.07. GuruFocus considers Biote to be Modestly Undervalued.

Key valuation signals for BTMD:

  • Other Current Payables: $-0.0 Mil
  • GF Value™: $3.07 vs. price of $2.28 (25.7% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
70GF Score

Get the complete analysis for BTMD

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.28
Price
$3.07
GF Value